Summary:
Eli Lilly received FDA approval for its oral GLP-1 weight-loss drug Foundayo (orforglipron), marking the start of competition in the oral obesity drug market.
The drug was approved in just 50 days, setting a record for the fastest approval of a new molecular entity since 2002
Foundayo is a once-daily oral pill with no food or water restrictions, priced from $25/month (insured) to $149–$349/month (self-pay), and will be distributed via LillyDirect and retail channels.
Clinical data show Foundayo delivers ~12.4% weight loss, lower than injectable drugs like Zepbound (>20%) and also below Novo Nordisk’s oral Wegovy (~16.6%).
Eli Lilly and Novo Nordisk are entering a new “oral GLP-1 competition phase”, with both pricing similarly but differing in convenience (Wegovy requires fasting conditions).
The global obesity drug market is shifting to a dual-track model (oral + injectable), where efficacy, price, and convenience will drive competition and expand patient adoption.
Comment:
Eli Lilly remains one of my preferred names in the healthcare space, consistently demonstrating strong growth and maintaining a leading position in the biotech and pharmaceutical industry. Its strength lies in being a truly R&D-driven company, with a deep focus on developing innovative, patented drugs rather than relying on generics. This model allows Eli Lilly to sustain both pricing power and long-term competitiveness, especially in high-impact areas such as obesity, diabetes, and oncology.
What makes Eli Lilly particularly compelling is not just its ability to innovate, but its ability to translate innovation into commercial success. The company has proven that it can bring drugs from research to market efficiently, supported by strong clinical execution, regulatory capability, and expanding manufacturing capacity. Its long-term investments in production—especially in GLP-1 therapies—position it well to capture growing global demand.
Another important factor is its pipeline depth and platform advantage. Eli Lilly is not relying on a single blockbuster, but is building an ecosystem of therapies within key disease areas, allowing it to compound growth over time. This reduces dependency risk and strengthens its leadership position within the industry.
From an investment perspective, while valuations may fluctuate and the stock can experience periods of deeper correction, Eli Lilly remains a company with strong structural drivers. When meaningful pullbacks occur, it stands out as a high-quality name worth considering for long-term holding, particularly for investors looking to gain exposure to the ongoing transformation in healthcare and biotech innovation.
Disclaimer:
The above content reflects personal views and market discussion only. It does not constitute any investment advice or recommendation to buy or sell. Investing involves risk, and readers should make their own assessments and bear responsibility for their own decisions.